drugset
drugset / Trial / NCT06801067

A Study of SER-155 to Treat Diarrhea in People on Immunotherapy

NCT06801067 ↗

Phase 1 Recruiting 15 enrolled Memorial Sloan Kettering Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out whether SER-155 may be a safe first treatment that causes few or mild side effects for people due to irEC.

Timeline

Start
2025-01-24
Primary completion
2027-01-24
Completion
2027-01-24

Drugs

EvaluationDrugModalityDoseRoute
Subject SER-155 Other / unclassified — Oral

Indications

diarrheal disease enterocolitis